CareDx, Inc. (NASDAQ:CDNA - Get Free Report)'s share price passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $18.09 and traded as high as $20.44. CareDx shares last traded at $20.02, with a volume of 936,620 shares changing hands.
Analysts Set New Price Targets
A number of brokerages have issued reports on CDNA. Wall Street Zen cut shares of CareDx from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Stephens reaffirmed an "overweight" rating and issued a $40.00 target price on shares of CareDx in a report on Monday, May 5th. The Goldman Sachs Group dropped their price target on CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. Finally, HC Wainwright restated a "neutral" rating and issued a $25.00 price target on shares of CareDx in a research report on Monday, May 5th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, CareDx has a consensus rating of "Moderate Buy" and a consensus target price of $30.33.
Get Our Latest Stock Analysis on CDNA
CareDx Trading Down 0.5%
The stock's 50 day moving average price is $18.09 and its two-hundred day moving average price is $19.68. The firm has a market capitalization of $1.11 billion, a PE ratio of 17.41 and a beta of 2.19.
CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.03. The firm had revenue of $84.69 million during the quarter, compared to analysts' expectations of $84.56 million. CareDx had a return on equity of 21.16% and a net margin of 19.79%. The firm's quarterly revenue was up 17.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.03) EPS. Analysts expect that CareDx, Inc. will post -0.9 earnings per share for the current year.
Insider Activity
In other news, Director Hannah Valantine sold 10,570 shares of the business's stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $19.16, for a total transaction of $202,521.20. Following the completion of the sale, the director directly owned 38,994 shares of the company's stock, valued at $747,125.04. The trade was a 21.33% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Christine Cournoyer sold 29,136 shares of the business's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $15.96, for a total transaction of $465,010.56. Following the sale, the director directly owned 37,045 shares of the company's stock, valued at $591,238.20. This represents a 44.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 139,078 shares of company stock valued at $2,419,915 over the last quarter. Insiders own 4.40% of the company's stock.
Institutional Trading of CareDx
A number of institutional investors have recently modified their holdings of CDNA. Sterling Capital Management LLC boosted its position in CareDx by 771.2% during the 4th quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock worth $27,000 after purchasing an additional 1,126 shares during the period. Tower Research Capital LLC TRC boosted its holdings in CareDx by 553.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company's stock worth $84,000 after acquiring an additional 3,322 shares during the period. State of Wyoming purchased a new position in CareDx in the 4th quarter worth approximately $91,000. PNC Financial Services Group Inc. boosted its holdings in CareDx by 20,200.0% in the 1st quarter. PNC Financial Services Group Inc. now owns 4,466 shares of the company's stock worth $79,000 after acquiring an additional 4,444 shares during the period. Finally, Morse Asset Management Inc purchased a new position in CareDx in the 1st quarter worth approximately $103,000.
CareDx Company Profile
(
Get Free Report)
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CareDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.
While CareDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
